Nociceptin and its metabolite attenuate U0126 (cas 109511-58-2)-induced memory impairment through a nociceptin opioid peptide (NOP) receptor-independent mechanism
-
Add time:07/24/2019 Source:sciencedirect.com
Nociceptin binds to nociceptin opioid peptide (NOP) receptors. We reported that although high doses of nociceptin impaired memory function and that these effects were mediated via NOP receptors, low doses of nociceptin attenuated the memory impairment, and these attenuating effects were not mediated via NOP receptors. Even very low doses of nociceptin were biologically active and suggested a certain binding site for this peptide, but the mechanism underlying this attenuating effect has not yet been elucidated. In the present study, we investigated the effect of an intrahippocampal injection (i.h.) of nociceptin on memory impairment induced by U0126, a MEK inhibitor, and Rp-cAMPS, a PKA inhibitor in a step-down type passive avoidance test. U0126 (2.63 nmol/mouse, i.h.) impaired memory formation and training-dependent phosphorylation of ERK2 in the hippocampus. Co-administration of nociceptin (10 fmol/mouse) significantly attenuated memory impairment, while it did not attenuate the inhibition of training-dependent phosphorylation of ERK2 induced by U0126. On the other hand, nociceptin did not attenuate memory impairment induced by Rp-cAMPS (0.448 nmol/mouse, i.h.). Nociceptin (1 fmol/mouse) also attenuated U0126 (5.26 nmol/mouse)-induced memory impairment in NOP receptor knockout mice. Nociceptin was reported to metabolize into fragments (1–13) and (14–17) in vivo, which showed pharmacological activities without affecting NOP receptors. Our findings showed that nociceptin (14–17) (1 fmol/mouse) also attenuated U0126-induced memory impairment, while nociceptin (1–13) (0.1–10 fmol/mouse) did not attenuate memory impairment. These results suggest a novel action site or mechanism for the attenuating effects of nociceptin and its metabolite, and the sequence of nociceptin (14–17) is a critical structure.
We also recommend Trading Suppliers and Manufacturers of U0126 (cas 109511-58-2). Pls Click Website Link as below: cas 109511-58-2 suppliers
Prev:Effects of MEK-Specific Inhibitor U0126 (cas 109511-58-2) on the Conidial Germination, Appressorium Production, and Pathogenicity of Setosphaeria turcica
Next:Prevention of LLC-PK1 cell overgrowth in a bioartificial renal tubule device using a MEK inhibitor, U0126 (cas 109511-58-2)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- MEK inhibitors: The chemistry and biological activity of U0126 (cas 109511-58-2), its analogs, and cyclization products07/28/2019
- Using U0126 (cas 109511-58-2) to dissect the role of the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade in the regulation of gene expression by endothelin-1 in cardiac myocytes07/27/2019
- Non-specific effects of the MEK inhibitors PD098,059 and U0126 (cas 109511-58-2) on glutamate release from hippocampal synaptosomes07/26/2019
- Prevention of LLC-PK1 cell overgrowth in a bioartificial renal tubule device using a MEK inhibitor, U0126 (cas 109511-58-2)07/25/2019
- Effects of MEK-Specific Inhibitor U0126 (cas 109511-58-2) on the Conidial Germination, Appressorium Production, and Pathogenicity of Setosphaeria turcica07/23/2019
- Quantitative NMR analysis of Erk activity and inhibition by U0126 (cas 109511-58-2) in a panel of patient-derived colorectal cancer cell lines07/22/2019
- Antiviral activity of the MEK-inhibitor U0126 (cas 109511-58-2) against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo07/20/2019
- mTOR inhibitor temsirolimus and MEK1/2 inhibitor U0126 (cas 109511-58-2) promote chromosomal instability and cell type-dependent phenotype changes of glioblastoma cells07/21/2019
- U0126 (cas 109511-58-2) attenuates ischemia/reperfusion-induced apoptosis and autophagy in myocardium through MEK/ERK/EGR-1 pathway07/19/2019


